Financial Performance - Calidi Biotherapeutics reported a net loss of $5.1 million, or $0.65 per share, for Q3 2024, compared to a net loss of $2.0 million, or $1.41 per share, for the same period in 2023[7]. - Research and development expenses decreased to $2.2 million in Q3 2024 from $3.3 million in Q3 2023[7]. - General and administrative expenses were $3.1 million for Q3 2024, down from $4.0 million in Q3 2023[8]. Funding and Financial Position - The company raised $2 million through a registered direct offering and concurrent private placement in October 2024[6]. - As of September 30, 2024, Calidi had approximately $1.9 million in cash and $0.2 million in restricted cash, consistent with December 31, 2023[8]. - Total current liabilities increased to $11.6 million as of September 30, 2024, compared to $10.2 million at the end of 2023[11]. - Total assets decreased to $6.7 million as of September 30, 2024, down from $10.0 million at the end of 2023[11]. - The accumulated deficit increased to $117.6 million as of September 30, 2024, compared to $99.6 million at the end of 2023[11]. Clinical Developments - The FDA cleared Northwestern University's IND application for Calidi's NeuroNova (CLD-101) clinical trial in high-grade glioma, expected to start in early 2025[4]. - Data on RTNova (CLD-400) was presented at multiple international conferences, highlighting its potential to target multiple tumor sites[5].

Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma.Presented data supporting RTNova (CLD-400), the company’s systemic antitumor virotherapy platform, at the International Oncolytic Virotherapy Conference (IOVC) in Rotterdam, Netherlands, the Society for Immunotherapy of Cancer (SITC) Annual Meeting, and at Immuno US 2024 in San Diego, California.Raised $2 million in a registered direct offering and concurrent private placement. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 or FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-40789 | --- | --- | --- | --- | |-------|-------|-----------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 86-2967193 ...

- RTNova, an innovative systemic antitumor enveloped virotherapy, unlocks new possibilities in cancer therapy - RTNova addresses challenges posed by untargetable and untreatable metastatic diseases, offering a potential transformative solution with wide-ranging applications SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) --  Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies and viral vectors, will pr ...

SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 2,050,000 shares of the Company’s common stock at a price of $1.00 per share of common stock in a registered direct offering. In addition, in ...

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants — ticker symbol CLDI WS — of Calidi Biotherapeutics, Inc. (the "Company"), each whole warrant exercisable for 1/10th of a share of common stock at an exercise price of $115.00 per whole sh ...

Exhibit 99.1 Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results - Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi's Adult Adipose Allogeneic (AAA) stem cell innovative programs - Strengthened team with the appointment of Dr. George E. Peoples, MD, FACS, adjunct professor of Surgical Oncology at MD Anderson Cancer Center, to the company's Board of Directors, and the addition of Mark Gilbert, MD, scientist emeritus at the Nationa ...

Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi's Adult Adipose Allogeneic (AAA) stem cell innovative programs Strengthened team with the appointment of Dr. George E. Peoples, MD, FACS, adjunct professor of Surgical Oncology at MD Anderson Cancer Center, to the company's Board of Directors, and the addition of Mark Gilbert, MD, scientist emeritus at the National Institutes of Health (NIH), to its Medical Advisory Board Received a new U.S. patent for the compa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-40789 Calidi Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 86-2967193 (State or other jurisdiction of incorporation or organization) ( ...

Core Insights - Calidi Biotherapeutics, Inc. announced a $2 million strategic investment by Dr. Ronald Rigor into its new subsidiary, Nova Cell, to advance its Adult Adipose Allogeneic (AAA) stem cell programs [1][7] - Dr. Rigor also invested an additional $1 million into Calidi to support its oncology pipeline [1] - The global stem cell therapy market is projected to grow from $14.5 billion in 2024 to $31.4 billion by 2030, with Calidi's AAA stem cell technology positioned to lead this market [3] Company Developments - Nova Cell will serve as an exclusive technology service provider for Dr. Rigor to develop innovative stem cell-based products, including anti-aging creams and lotions for the Philippines [2] - Calidi's AAA stem cell technology is expected to generate revenue by supplying stem cells to Dr. Rigor's patients starting in 2025 [3] - The establishment of Nova Cell enhances strategic focus and resource allocation for both Calidi and Nova Cell, with Calidi concentrating on cancer therapies and Nova Cell on regenerative treatments [3] Investment Details - Dr. Rigor's investment includes a $1 million subscription agreement for Calidi common stock at a 10% discount and warrants for 600,000 shares at a 20% premium [7] - The investment aims to unlock the potential of off-the-shelf AAA stem cells through Calidi's advanced cellular manufacturing process [7] Market Position - Calidi Biotherapeutics is a clinical-stage immuno-oncology company utilizing proprietary technology to enhance the immune system's ability to fight cancer [4] - The company has been harvesting AAA stem cells from healthy adult donors for five years, adhering to FDA guidelines, and is now expanding applications beyond oncology to fields like cosmetics and orthopedics [8] - Dr. Rigor, as a leading figure in stem cell therapy in the Philippines, aims to elevate the health and wellness industry through this partnership with Nova Cell [9]